| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40106cc9ea41f423203ebf6017f53349
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_faf522b8b83eded745c73018576219ba |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-7158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70503
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70589
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70578
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70553
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-525 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2015-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15dbd7b4904d317a3961b10b09023c25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2468715b49c9e9f2be3fbfbeb47b15f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6605d04f05b3f2f7ade6a014fd4a5fb8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cced20ef470cc3c308443262880c6b3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44e38482a7d70ff408fb12a3b117562e |
| publicationDate |
2020-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10746726-B2 |
| titleOfInvention |
Method for assessing therapeutic effect of anti-cancer agent having anti-CD4 antibody as active ingredient |
| abstract |
Means that enables monitoring of an anticancer effect of an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint is disclosed. The method for testing a therapeutic effect of a cancer therapy of the present invention is a method for testing a therapeutic effect of an anticancer drug comprising as an effective ingredient an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint, which method comprises investigation of expression of (1) at least one immune checkpoint receptor, (2) CD8, and (3) at least one cell surface molecule selected from the group consisting of CD44 and CD45RO, on T cells using a sample derived from a patient who received the anticancer drug. Induction of a T cell population which is positive for the immune checkpoint molecule (1) and positive for CD8, and which shows high expression of CD44 and/or high expression of CD45RO, indicates that said anticancer drug is producing a therapeutic effect in said patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11168137-B2 |
| priorityDate |
2014-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |